| Item 2.02 | Results of Operations and Financial Condition. |
On February 7, 2023, Magenta Therapeutics, Inc. (the “Company” or “Magenta”) announced that as of December 31, 2022, the Company’s cash, cash equivalents and marketable securities were approximately $112 million.
The cash, cash equivalents and marketable securities information above is based on preliminary unaudited information and management estimates for the year ended December 31, 2022, is not a comprehensive statement of the Company’s financial results as of and for the fiscal year ended December 31, 2022 and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate.
The information contained in this item is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 2.05 | Costs Associated with Exit or Disposal Activities. |
On February 6, 2023, the Board of Directors (the “Board”) of the Company approved a restructuring plan (the “Plan”) to reduce the Company’s operations to preserve financial resources, resulting in a reduction of the Company’s workforce by up to 56 positions, or approximately 84%, to be substantially completed by February 17, 2023. As a result of the Plan, the Company expects to incur estimated severance and related costs of $5.4 million by the end of February 2023.
Each departing employee of Magenta has played an integral role in the Company’s mission of improving stem cell transplant to enable access for more patients. Magenta would like to sincerely thank its departing employees for their hard work and dedication, and the Company wishes them well in their future endeavors.
As the Plan is implemented, the Company’s management will re-evaluate the estimated costs and expenses set forth above and may revise the estimated restructuring charge as appropriate, consistent with generally accepted accounting principles. The estimated charges that the Company expects to incur in connection with the Plan are subject to a number of assumptions, and actual results may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Plan.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. |
In connection with the Plan, as discussed in Item 2.05 above, the following members of the Company’s executive team, (i) Jason Gardner, President and Chief Executive Officer, (ii) David Nichols, Chief Technical Officer, (iii) Caren Deardorf, Chief Commercial Officer, (iv) Kristen Stants, Chief People Officer and (v) Shawn Rose, Senior Vice President and Head of Clinical Development, will be leaving the Company to pursue new opportunities. The Company plans to enter into consulting agreements with Dr. Gardner, Mr. Nichols and Ms. Deardorf on terms yet to be determined, but are contemplated to be on an as requested basis and at an hourly rate for work performed. Dr. Gardner will no longer serve as a director of the Company, effective as of February 7, 2023. Dr. Gardner’s resignation from the Board was not due to any disagreement with the Company’s operations, policies or practices.
Magenta would like to thank Dr. Gardner, Mr. Nichols, Ms. Deardorf, Ms. Stants and Dr. Rose for their commitment and guidance to the Company.
Each departing member of the Company’s executive team will be entitled to receive severance upon the execution of a separation agreement satisfactory to Magenta. Assuming the execution of this agreement, (i) Dr. Gardner will be entitled to receive severance benefits pursuant to the terms of his Amended and Restated Employment Agreement with the Company, with an effective date of March 3, 2022, attached as Exhibit 10.12 to our Annual Report on Form 10-K filed with the SEC on March 8, 2023, and (ii) Mr. Nichols will be entitled to receive severance benefits pursuant to the terms of his Amended and Restated Employment Agreement with the Company, with an effective date of May 2, 2022, attached as Exhibit 10.2 to our Current Report on Form 8-K filed with the SEC on May 2, 2022.
2
